WO2013109205A1 - Pharmaceutical tablet formulations comprising cefetamet - Google Patents

Pharmaceutical tablet formulations comprising cefetamet Download PDF

Info

Publication number
WO2013109205A1
WO2013109205A1 PCT/TR2013/000017 TR2013000017W WO2013109205A1 WO 2013109205 A1 WO2013109205 A1 WO 2013109205A1 TR 2013000017 W TR2013000017 W TR 2013000017W WO 2013109205 A1 WO2013109205 A1 WO 2013109205A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet formulation
cefetamet
formulation according
disintegrant
pharmaceutical tablet
Prior art date
Application number
PCT/TR2013/000017
Other languages
French (fr)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013109205A1 publication Critical patent/WO2013109205A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to pharmaceutical tablet formulations comprising cefetamet to be used in the treatment of infectious diseases caused by gram positive and gram negative bacteria.
  • Cefetamet was firstly disclosed in the patent application numbered US4396618. In said document, cefetamet was indicated to be effective in the treatment of infectious diseases caused by gram positive and gram negative bacteria.
  • Cefetamet is available in the form of 250 mg and 500 mg oral tablets on the market.
  • tablet hardness In pharmaceutical tablet formulations one of the important physical parameters is tablet hardness. Achieving the desired hardness provides the resistance of tablets to storage, transport, coating, compression and erosion-breakage before usage. Tablets with low hardness are more sensitive to erosion, friability or breakage and this case causes loss of active agent and thus decreases the amount of the dose taken. Another consequence of low hardness is the erosion of tablet surface during coating process and obtainment of dosage forms which have uneven surfaces and variable amounts of active agent in the final product while producing coated tablet forms. On the other hand, there is a close connection between tablet hardness and dispersibility and solubility of a tablet. Tablets that are too hard do not disperse or dissolve adequately; in this case, bioavailability of said dosage forms will decrease and therefore the time for desired biological response to occur will extend.
  • the choice of excipients and their amount are also important parameters for obtaining required tablet formulation.
  • the content of the formulation affects the resistance of tablets to processes such as coating and compression and prevents the adherence of the formulation to the machine parts thus the loss of active agent and ensures the amount of the dose taken. Therefore, the aim of the present invention is to obtain tablets having required solubility and hardness good enough to be dissolved adequately and resistant to storage, transport, coating, compression and erosion-breakage before usage.
  • the inventors of the present invention have conducted studies on pharmaceutical tablet formulations comprising cefetamet and have found that the desired mechanical tablet hardness corresponding to the desired dissolution rate is obtained when the ratio of cefetamet to the amount of disintegrant used is 5:1 to 1 :5, preferably 4:1 to 1 : 1 by weight.
  • pharmaceutical tablet formulations comprising cefetamet as active agent of the present invention is characterized in that the ratio of cefetamet to the amount of disintegrant is 5:1 to 1 :5 by weight.
  • the present invention is related to the tablet formulations wherein the ratio of cefetamet to the amount of disintegrant is 4:1 to 1 :1 by weight.
  • the disintegrants used in the formulations of the present invention can be selected from a group comprising microcrystalline cellulose, crosspovidone, croscarmellose sodium, carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, hydroxypropyl cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate.
  • a further embodiment of the present invention is that the disintegrant used in the formulations of the present invention is preferably croscarmellose sodium.
  • the ratio of cefetamet to croscarmellose sodium is 5:1 to 1 :5, preferably 4:1 to 1 :1 by weight.
  • a further need during the preparation of cefetamet tablet formulations is that the core tablet has the required mechanical properties to endure the coating process and not to lose the active agent.
  • the inventors have conducted studies on the core tablet and the coating and found out that the disintegrant should be added to the formulation in two different stages namely; before lubrication and during lubrication and the ratio of disintegrant used before lubrication to disintegrant used during lubrication should be 10:1 to 1 :1, preferably 8:1 to 1 : 1, more preferably 6:1 to 2:1 by weight.
  • a preferred embodiment of the present invention is the pharmaceutical tablet formulation comprising cefetamet which is characterized in that the ratio of disintegrant used before lubrication to disintegrant used during the lubrication is 10: 1 to 1 :1 , preferably 8:1 to 1 :1, more preferably 6: 1. to 2:1 by weight.
  • the pharmaceutical tablet formulations of the present invention can be in the form of any of tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet dosage forms.
  • pharmaceutical tablet formulations are in the form of film-coated tablet.
  • the pharmaceutical tablet formulation of the present invention can be treated with film coating agents such as sugar-based coating agents, water-soluble film coating agents, enteric coating agents and delayed release coating agents or a coating composition comprising any combination thereof.
  • film coating agents such as sugar-based coating agents, water-soluble film coating agents, enteric coating agents and delayed release coating agents or a coating composition comprising any combination thereof.
  • saccharose can be used alone or together with any of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or any combination thereof.
  • agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or any combination thereof.
  • Water-soluble film coating agents can be selected from a group comprising cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl amino acetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone; polysaccharides such as pullulan or combinations thereof.
  • cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose
  • synthetic polymers such as polyvinyl acetal diethyl amino acetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone
  • polysaccharides such as pullulan or combinations thereof.
  • Enteric coating agents can be selected from a group comprising cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S and natural substances such as shellac or combinations thereof.
  • cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate
  • acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S and natural substances such as shellac or combinations thereof.
  • film coating agents can be selected from a group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin and/or combinations thereof.
  • a film coating agent branded as Opadry® can be used in the present invention.
  • cefetamet is in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof in terms of chemical structure; and in amorphous or crystalline forms or combinations thereof in. terms of polymorphic structure.
  • cefetamet is in the form of pharmaceutically acceptable cefetamet pivoxil.
  • the pharmaceutical formulations of the present invention comprise at least one pharmaceutically acceptable excipient in addition to disintegrant selected from the group comprising diluents, lubricants, pH regulating agents.
  • the diluent that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol or combinations thereof.
  • the diluent used is microcrystalline cellulose.
  • the amount of disintegrant to the amount of diluent should be 5:1 to 1 :5 by weight in order to have tablets with desired mechanical parameters.
  • the ratio of disintegrant to diluent is 5:1 to 1 :5, preferably 3: 1 to 1 :3 by weight.
  • the ratio of croscarmellose sodium to microcrystalline cellulose is 5:1 to 1 :5, preferably 3: 1 to 1 :3 by weight.
  • the lubricant that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
  • cefetamet tablet formulations Another problem in cefetamet tablet formulations is observed during the compression step.
  • the compression force applied on the tablet causes adherence of the formulation to the parts of the compression machine and loss of the active agent if lubrication is not performed with required parameters.
  • the inventors have surprisingly found out that if the disintegrant is added to the formulation in two different stages namely; before lubrication and during lubrication and the ratio of lubricant used before lubrication to lubricant used during lubrication is 9:1 to 1 :1, preferably 6:1 to 1 :1, more preferably 4: 1 to 1 :1 by weight, there is no loss of the active agent due to the adherence of the formulation.
  • a preferred embodiment of the present invention is that the pharmaceutical tablet formulation comprising cefetamet which is characterized in that the ratio of lubricant used before lubrication to lubricant used during lubrication is 9:1 to 1 :1, preferably 6:1 to 1 :1, more preferably 4: 1 to 1 : 1 by weight.
  • the pharmaceutical formulations of the invention comprising cefetamet as active agent comprise cefetamet in the range of 30-80%, more preferably in the range of 40-65% by weight.
  • the pharmaceutical formulation of the invention comprises 30 to 80% of cefetamet, 10 to 30% of disintegrant, 10 to 25% of diluent, 1 to 10% of lubricant, 3 to 10% of pH regulating agent and 1 to 10% of film coating agent in proportion to total weight of the formulation.
  • the pharmaceutical formulation of the invention can be obtained by a method comprising the steps of a. Mixing cefetamet with disintegrant and at least one pharmaceutically acceptable excipient to obtain a first mixture,
  • Lubricant is added to first mixture and the blend is dry granulated by slugging/deslugging,
  • Formed slugs are mixed with disintegrant and at least one pharmaceutically acceptable excipient,
  • Lubrication is performed with the lubricant and the blend is compressed into tablet form
  • Obtained tablets are coated with a coating solution containing a film-coating agent.
  • the pharmaceutical formulation of the invention can be used in the treatment of the infectious diseases caused by gram positive and gram negative bacteria.
  • Example 1 Tablet formulations comprising cefetamet
  • a first mixture is formed by mixing cefetamet with disintegrant, diluent, pH regulating agent and lubricant.
  • the first mixture is sieved and lubricant is added.
  • the blend is dry granulated by slugging/deslugging. Formed slugs are mixed with disintegrant and diluent.
  • Lubrication is performed with the lubricant and the blend is compressed into tablet form. Obtained tablets are coated with a coating solution containing a film-coating agent.

Abstract

The present invention relates to pharmaceutical tablet formulations comprising cefetamet to be used in the treatment of infectious diseases caused by gram positive and gram negative bacteria.

Description

PHARMACEUTICAL TABLET FORMULATIONS COMPRISING CEFETAMET
The present invention relates to pharmaceutical tablet formulations comprising cefetamet to be used in the treatment of infectious diseases caused by gram positive and gram negative bacteria. Cefetamet was firstly disclosed in the patent application numbered US4396618. In said document, cefetamet was indicated to be effective in the treatment of infectious diseases caused by gram positive and gram negative bacteria.
Cefetamet is available in the form of 250 mg and 500 mg oral tablets on the market.
In terms of pharmaceutical technology, physical properties of every tablet dosage form are directly related to durability in storage conditions; dissolution and bioavailability of an obtained dosage form.
In pharmaceutical tablet formulations one of the important physical parameters is tablet hardness. Achieving the desired hardness provides the resistance of tablets to storage, transport, coating, compression and erosion-breakage before usage. Tablets with low hardness are more sensitive to erosion, friability or breakage and this case causes loss of active agent and thus decreases the amount of the dose taken. Another consequence of low hardness is the erosion of tablet surface during coating process and obtainment of dosage forms which have uneven surfaces and variable amounts of active agent in the final product while producing coated tablet forms. On the other hand, there is a close connection between tablet hardness and dispersibility and solubility of a tablet. Tablets that are too hard do not disperse or dissolve adequately; in this case, bioavailability of said dosage forms will decrease and therefore the time for desired biological response to occur will extend.
Furthermore, the choice of excipients and their amount are also important parameters for obtaining required tablet formulation. The content of the formulation affects the resistance of tablets to processes such as coating and compression and prevents the adherence of the formulation to the machine parts thus the loss of active agent and ensures the amount of the dose taken. Therefore, the aim of the present invention is to obtain tablets having required solubility and hardness good enough to be dissolved adequately and resistant to storage, transport, coating, compression and erosion-breakage before usage.
In order to achieve this aim, the inventors of the present invention have conducted studies on pharmaceutical tablet formulations comprising cefetamet and have found that the desired mechanical tablet hardness corresponding to the desired dissolution rate is obtained when the ratio of cefetamet to the amount of disintegrant used is 5:1 to 1 :5, preferably 4:1 to 1 : 1 by weight.
According to this, pharmaceutical tablet formulations comprising cefetamet as active agent of the present invention is characterized in that the ratio of cefetamet to the amount of disintegrant is 5:1 to 1 :5 by weight.
In a preferred embodiment, the present invention is related to the tablet formulations wherein the ratio of cefetamet to the amount of disintegrant is 4:1 to 1 :1 by weight.
The disintegrants used in the formulations of the present invention can be selected from a group comprising microcrystalline cellulose, crosspovidone, croscarmellose sodium, carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, hydroxypropyl cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate.
A further embodiment of the present invention is that the disintegrant used in the formulations of the present invention is preferably croscarmellose sodium. In another embodiment of the present invention, the ratio of cefetamet to croscarmellose sodium is 5:1 to 1 :5, preferably 4:1 to 1 :1 by weight. A further need during the preparation of cefetamet tablet formulations is that the core tablet has the required mechanical properties to endure the coating process and not to lose the active agent. In order to ensure this feature of the core, the inventors have conducted studies on the core tablet and the coating and found out that the disintegrant should be added to the formulation in two different stages namely; before lubrication and during lubrication and the ratio of disintegrant used before lubrication to disintegrant used during lubrication should be 10:1 to 1 :1, preferably 8:1 to 1 : 1, more preferably 6:1 to 2:1 by weight.
According to this, a preferred embodiment of the present invention is the pharmaceutical tablet formulation comprising cefetamet which is characterized in that the ratio of disintegrant used before lubrication to disintegrant used during the lubrication is 10: 1 to 1 :1 , preferably 8:1 to 1 :1, more preferably 6: 1. to 2:1 by weight.
The pharmaceutical tablet formulations of the present invention can be in the form of any of tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet dosage forms.
In a preferred embodiment of the invention, pharmaceutical tablet formulations are in the form of film-coated tablet.
The pharmaceutical tablet formulation of the present invention can be treated with film coating agents such as sugar-based coating agents, water-soluble film coating agents, enteric coating agents and delayed release coating agents or a coating composition comprising any combination thereof.
As sugar-based coating agent, saccharose can be used alone or together with any of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or any combination thereof.
Water-soluble film coating agents can be selected from a group comprising cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl amino acetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone; polysaccharides such as pullulan or combinations thereof.
Enteric coating agents can be selected from a group comprising cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S and natural substances such as shellac or combinations thereof.
Other film coating agents can be selected from a group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin and/or combinations thereof. For example, a film coating agent branded as Opadry® can be used in the present invention.
A further embodiment of the present invention is that cefetamet is in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof in terms of chemical structure; and in amorphous or crystalline forms or combinations thereof in. terms of polymorphic structure.
A preferred embodiment of the present invention is that cefetamet is in the form of pharmaceutically acceptable cefetamet pivoxil. The pharmaceutical formulations of the present invention comprise at least one pharmaceutically acceptable excipient in addition to disintegrant selected from the group comprising diluents, lubricants, pH regulating agents.
The diluent that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol or combinations thereof.
According to a preferred embodiment of the present invention, the diluent used is microcrystalline cellulose. During the development studies of tablet formulations comprising cefetamet, the inventors have observed that the tablets are more resistant to erosion and breakage before use if the weight of disintegrant and diluent they contain is adjusted. Consequently, the inventors have found out that the amount of disintegrant to the amount of diluent should be 5:1 to 1 :5 by weight in order to have tablets with desired mechanical parameters. According to this, in a preferred embodiment of the present invention, the ratio of disintegrant to diluent is 5:1 to 1 :5, preferably 3: 1 to 1 :3 by weight.
In a more preferred embodiment of the invention, the ratio of croscarmellose sodium to microcrystalline cellulose is 5:1 to 1 :5, preferably 3: 1 to 1 :3 by weight.
The lubricant that can be used in the pharmaceutical formulations of the invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
Another problem in cefetamet tablet formulations is observed during the compression step. The compression force applied on the tablet causes adherence of the formulation to the parts of the compression machine and loss of the active agent if lubrication is not performed with required parameters. The inventors have surprisingly found out that if the disintegrant is added to the formulation in two different stages namely; before lubrication and during lubrication and the ratio of lubricant used before lubrication to lubricant used during lubrication is 9:1 to 1 :1, preferably 6:1 to 1 :1, more preferably 4: 1 to 1 :1 by weight, there is no loss of the active agent due to the adherence of the formulation.
Based on the abovementioned observation, a preferred embodiment of the present invention is that the pharmaceutical tablet formulation comprising cefetamet which is characterized in that the ratio of lubricant used before lubrication to lubricant used during lubrication is 9:1 to 1 :1, preferably 6:1 to 1 :1, more preferably 4: 1 to 1 : 1 by weight.
In a preferred embodiment of the invention, the pharmaceutical formulations of the invention comprising cefetamet as active agent comprise cefetamet in the range of 30-80%, more preferably in the range of 40-65% by weight.
In a further preferred embodiment of the invention, the pharmaceutical formulation of the invention comprises 30 to 80% of cefetamet, 10 to 30% of disintegrant, 10 to 25% of diluent, 1 to 10% of lubricant, 3 to 10% of pH regulating agent and 1 to 10% of film coating agent in proportion to total weight of the formulation.
According to a preferred embodiment of the invention, the pharmaceutical formulation of the invention can be obtained by a method comprising the steps of a. Mixing cefetamet with disintegrant and at least one pharmaceutically acceptable excipient to obtain a first mixture,
b. Lubricant is added to first mixture and the blend is dry granulated by slugging/deslugging,
c. Formed slugs are mixed with disintegrant and at least one pharmaceutically acceptable excipient,
d. Lubrication is performed with the lubricant and the blend is compressed into tablet form,
e. Obtained tablets are coated with a coating solution containing a film-coating agent. in a preferred embodiment of the invention, the pharmaceutical formulation of the invention can be used in the treatment of the infectious diseases caused by gram positive and gram negative bacteria.
Example 1: Tablet formulations comprising cefetamet
Figure imgf000007_0001
In obtainment of the formulation to be used in scope of the present invention, a first mixture is formed by mixing cefetamet with disintegrant, diluent, pH regulating agent and lubricant. The first mixture is sieved and lubricant is added. Then the blend is dry granulated by slugging/deslugging. Formed slugs are mixed with disintegrant and diluent. Lubrication is performed with the lubricant and the blend is compressed into tablet form. Obtained tablets are coated with a coating solution containing a film-coating agent.

Claims

1. A pharmaceutical tablet formulation comprising cefetamet as active agent with at least one pharmaceutically acceptable excipient, characterized in that the ratio of cefetamet to the amount of disintegrant is 5 : 1 to 1 :5 by weight.
2. A pharmaceutical tablet formulation according to claim 1, characterized in that the ratio of cefetamet to the amount of disintegrant used is 4: 1 to 1 : 1 by weight.
3. A pharmaceutical tablet formulation according to claims 1-2, wherein the disintegrant is selected from a group comprising microcrystalline cellulose, crosspovidone, croscarmellose sodium, carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, hydroxypropyl cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate.
4. The pharmaceutical tablet formulation according to claim 3, wherein the disintegrant is croscarmellose sodium.
5. The pharmaceutical tablet formulation according to any one of the preceding claims, characterized in that said tablet formulations is in the form of any of tablet, effervescent tablet, film-coated tablet, enteric-coated tablet, orodispersible tablet, water-soluble tablet, extended-release tablet, modified-release tablet, delayed-release tablet dosage forms.
6. The pharmaceutical tablet formulation according to claim 5, characterized in that said tablet formulation is in the form of film-coated tablet.
7. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that cefetamet is in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof in terms of chemical structure; and in amorphous or crystalline forms or combinations thereof in terms of polymorphic structure.
8. The pharmaceutical tablet formulation according to claim 7, characterized in that cefetamet is in the form of cefetamet pivoxil.
9. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that at least one pharmaceutically acceptable excipient to be used with cefetamet is selected from the group comprising diluents, lubricants, pH regulating agents.
10. The pharmaceutical tablet formulation according to claim 9, wherein the diluent is selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol or combinations thereof.
11. The pharmaceutical tablet formulation according to claim 9, wherein the lubricant is selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate or combinations thereof.
12. The pharmaceutical tablet formulation according to claim 9, wherein the pH regulating agent is selected form a group comprising citrate, phosphate, carbonate, tartarate, fumarate, acetate and amino acid salts or combinations thereof.
13. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that said tablet formulation comprises cefetamet in the range of 30- 80% by weight.
14. The pharmaceutical tablet formulation according to claim 13, characterized in that said tablet formulation comprises cefetamet in the range of 40-65% by weight.
15. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that the ratio of the amount of disintegrant to the amount of diluent is 5:1 to 1 :5 by weight.
16. The pharmaceutical tablet formulation according to claim 15, characterized in that the ratio of the amount of disintegrant to the amount of diluent is 3:1 to 1 :3 by weight.
17. The pharmaceutical tablet formulation according to any of the preceding claims, characterized in that lubricant and disintegrant used in the formulation are added in two different stages namely; before lubrication and during lubrication.
18. The pharmaceutical tablet formulation according to claim 17, characterized in that the ratio of disintegrant used before lubrication to disintegrant used during lubrication is 10:1 to 1 : 1 by weight.
19. The pharmaceutical tablet formulation according to claim 18, characterized in that the ratio of disintegrant used before lubrication to disintegrant used during lubrication is 8:1 to 1 :1 by weight.
20. The pharmaceutical tablet formulation according to claim 17, characterized in that the ratio of lubricant used before lubrication to lubricant used during lubrication is 9: 1 to 1 : 1 by weight.
21. The pharmaceutical tablet formulation according to claim 20, characterized in that the ratio of lubricant used before lubrication to lubricant used during lubrication is 6: 1 to 1 : 1 by weight.
22. The pharmaceutical tablet formulation comprising cefetamet according to any preceding claim, wherein said formulation comprises 30 to 80% of cefetamet, 10 to 30% of disintegrant, 10 to 25% of diluent, 1 to 10% of lubricant, 3 to 10% of pH regulating agent and 1 to 10% of film coating agent in proportion to total weight of the formulation.
23. The method for the preparation of a pharmaceutical composition according to any preceding claims, wherein said method comprises a process of
a. Mixing cefetamet with disintegrant and at least one pharmaceutically acceptable excipient to obtain a first mixture,
b. Lubricant is added to first mixture and the blend is dry granulated by slugging/deslugging,
c. Formed slugs are mixed with disintegrant and at least one pharmaceutically acceptable excipient,
d. Lubrication is performed with the lubricant and the blend is compressed into tablet form,
e. Obtained tablets are coated with a coating solution containing a film-coating agent.
PCT/TR2013/000017 2012-01-18 2013-01-16 Pharmaceutical tablet formulations comprising cefetamet WO2013109205A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/00596 2012-01-18
TR201200596 2012-01-18

Publications (1)

Publication Number Publication Date
WO2013109205A1 true WO2013109205A1 (en) 2013-07-25

Family

ID=47913527

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2013/000014 WO2013109202A2 (en) 2012-01-18 2013-01-16 Pharmaceutical compounds comprising cefetamet
PCT/TR2013/000017 WO2013109205A1 (en) 2012-01-18 2013-01-16 Pharmaceutical tablet formulations comprising cefetamet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000014 WO2013109202A2 (en) 2012-01-18 2013-01-16 Pharmaceutical compounds comprising cefetamet

Country Status (1)

Country Link
WO (2) WO2013109202A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800221A (en) * 2015-05-15 2015-07-29 苗怡文 Medicinal cefetamet pivoxil hydrochloride composition for treating sensitive bacteria infectious diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396618A (en) 1976-03-25 1983-08-02 Roussel Uclaf Alkyloximes of 7-amino-thiazolyl-acetamido-cephalosporanic acids
WO2004019901A2 (en) * 2002-08-30 2004-03-11 Orchid Chemicals & Pharmaceuticals Ltd. Sustained release pharmaceutical composition
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
EP1782830A1 (en) * 2004-08-10 2007-05-09 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing ep4 agonist
WO2011139255A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising cefetamet

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396618A (en) 1976-03-25 1983-08-02 Roussel Uclaf Alkyloximes of 7-amino-thiazolyl-acetamido-cephalosporanic acids
WO2004019901A2 (en) * 2002-08-30 2004-03-11 Orchid Chemicals & Pharmaceuticals Ltd. Sustained release pharmaceutical composition
EP1782830A1 (en) * 2004-08-10 2007-05-09 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing ep4 agonist
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
WO2011139255A2 (en) * 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising cefetamet

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M P DUCHARME ET AL: "Bioavailability of syrup and tablet formulations of cefetamet pivoxil.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 37, no. 12, 1 December 1993 (1993-12-01), pages 2706 - 2709, XP055060355, ISSN: 0066-4804, DOI: 10.1128/AAC.37.12.2706 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800221A (en) * 2015-05-15 2015-07-29 苗怡文 Medicinal cefetamet pivoxil hydrochloride composition for treating sensitive bacteria infectious diseases
CN106176759A (en) * 2015-05-15 2016-12-07 烟台市华文欣欣医药科技有限公司 A kind of cefetamet pivoxil hydrochloride tablets agent compositions

Also Published As

Publication number Publication date
WO2013109202A3 (en) 2014-03-20
WO2013109202A2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
CN105848647B (en) Pharmaceutical compositions comprising AZD9291
EP2854759B1 (en) Dosage forms comprising apixaban and matrix former
JP2013530196A (en) Pharmaceutical composition comprising 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinolin-2-one lactate monohydrate object
US9393205B2 (en) Gastroretentive tablets
JP5417662B2 (en) Nevirapine sustained release formulation
EP3383397B1 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
EP2902016A1 (en) Febuxostat tablet
WO2012005359A1 (en) Orally disintegrating tablet
WO2017208136A1 (en) Pharmaceutical composition of dapagliflozin co-crystal
CA3089537A1 (en) Pharmaceutical compositions comprising ibrutinib
US20150182629A1 (en) Stable compositions of fesoterodine
EP3437645B1 (en) Film-coated tablet having high chemical stability of active ingredient
WO2009027786A2 (en) Matrix dosage forms of varenicline
WO2013100880A1 (en) Formulations comprising cefuroxime
WO2010120963A1 (en) Tablet formulation for p38 inhibitor and method
WO2013109205A1 (en) Pharmaceutical tablet formulations comprising cefetamet
WO2017037645A1 (en) Stable pharmaceutical formulations of teriflunomide
US20080260785A1 (en) Paroxetine compositions
US20080081069A1 (en) Novel controlled release formulations of divalproex sodium
JP7117975B2 (en) Pharmaceutical composition containing teneligliptin, method for producing pharmaceutical composition containing teneligliptin, tablet containing teneligliptin, and method for producing tablet containing teneligliptin
WO2013109226A1 (en) Pharmaceutical tablet formulations comprising cefuroxime
JP2021518422A (en) Pharmaceutical composition containing lenalidomide
WO2013109203A1 (en) Tablet formulations comprising cefditoren pivoxil
WO2013109229A1 (en) Tablet formulations comprising cefixime as active agent
WO2013100879A1 (en) Pharmaceutical compositions comprising quetiapine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13711154

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13711154

Country of ref document: EP

Kind code of ref document: A1